# Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes

**The EUGenMed[†], Cardiovascular Clinical Study Group, Vera Regitz-Zagrosek[1,2,3]\*,
Sabine Oertelt-Prigione[1,2,3], Eva Prescott[4], Flavia Franconi[2,5], Eva Gerdts[6],
Anna Foryst-Ludwig[3,7], Angela H.E.M. Maas[8], Alexandra Kautzky-Willer[2,9],
Dorit Knappe-Wegner[2,10], Ulrich Kintscher[3,7], Karl Heinz Ladwig[11],
Karin Schenck-Gustafsson[2,12], and Verena Stangl[3,13]**

[1]Institute of Gender in Medicine, Center for Cardiovascular Research, Charité - Universitätsmedizin Berlin, Hessische Str. 3-4, 10115 Berlin, Germany; [2]International Society for Gender Medicine; [3]DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany; [4]Bispebjerg Hospital, University of Copenhagen, Bispebjerg Bakke 23, 2400 Copenhagen, Denmark; [5]Dep Scienze Biomediche, Regione Basilicata and National Laboratory of Gender Medicine, Consorzio Interuniversitario INBB, University of Sassari, Via Muroni 23a, 07100 Sassari, Italy; [6]Department of Clinical Science, University of Bergen, PO Box 7804, 5020 Bergen, Norway; [7]Institute of Pharmacology, Center for Cardiovascular Research, Charité - Universitätsmedizin Berlin, Hessische Str. 3-4, 10115 Berlin, Germany; [8]Department of Cardiology, Radboud University Medical Center, Geert Grooteplein-Zuid 10, Route 616, 6525 GA Nijmegen, The Netherlands; [9]Gender Medicine Unit, Internal Medicine III, Endocrinology, Medical University of Vienna, International Society for Gender Medicine, Währinger Gürtel 18-20, 1090 Vienna, Austria; [10]University Heart Center Hamburg, Martinistrasse 52, 20246 Hamburg, Germany; [11]Helmholtz Center Munich, Institute of Epidemiology II, German Research Center for Environmental Health, Ingolstädter Landstr. 1, 85764 Neuherberg, Germany; [12]Karolinska Institutet Stockholm, Centre for Gender Medicine, Thorax N3:05, International Society for Gender Medicine, 17176 Stockholm, Sweden; and [13]Clinic for Cardiology and Angiology, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany

## Introduction

In the vast majority of cardiovascular diseases (CVDs), there are well-described differences between women and men in epidemiology, pathophysiology, clinical manifestations, effects of therapy, and outcomes.[1–3] These differences arise on one hand from biological differences among women and men, which are called sex differences. They are due to differences in gene expression from the sex chromosomes and subsequent differences in sexual hormones leading to differences in gene expression and function in the CV system, e.g. in vascular function and NO signalling, in myocardial remodelling under stress, or metabolism of drugs by sex-specific cytochrome expression. Sex differences are frequently reproducible in animal models. In contrast, gender differences are unique to the human. They arise from sociocultural processes, such as different behaviours of women and men; exposure to specific influences of the environment; different forms of nutrition, lifestyle, or stress; or attitudes towards treatments and prevention. These are equally important for CVDs. Both sex and gender (S&G) influence human development (*Figure 1*). Since it is almost impossible to distinguish properly between effects of S&G in the medical field, the EUGenMed writing group decided to discuss

both of them together and to use the term S&G for all medical relevant differences between women and men in the present review.

In its current research framework programme 'Horizon 2020', the EU calls for the inclusion of the gender dimension into biomedical research since 'it helps improve the scientific quality and societal relevance of the produced knowledge, technology and/or innovation' (http://ec.europa.eu/programmes/horizon2020/en/h2020-section/promoting-gender-equality-research-and-innovation). The US National Institutes of Health and medicine regulating agencies, such as the European Medicines Agency or the US Food and Drug Administration (FDA), ask for information on potential sex differences for all new drugs and require prespecifications for testing sex effects in drug studies. In 2001, the US government published the results of a retrospective assessment of the drugs withdrawn by the FDA between 1997 and 2000 due to adverse effects, and discovered that these drugs posed greater health risks to women than men.[4] Inclusion of information about S&G is becoming a primary focus of the ongoing debate about the improvement of scientific validity and reproducibility, with the eventual goal to improve translation.[5] It is also a major aspect in optimizing daily patient care.[6,7] Even so a number of efforts have been made to obtain gender-specific data on

---

**Figure I** Interaction between sex and gender during lifetime: societal conditions (upper) as well as biological facts (lower) affect germ cells, the newborn, the adult, and the development of disease in women and men.

cardiovascular risk, as in the score project, S&G differences are still frequently missing in current CVD textbooks or guidelines.[8]

There is a lot of published knowledge on S&G differences, but the awareness is low. This may be due to the fact that existing knowledge is dispersed and not presented in a coherent manner. The present review aims to close the gap in knowledge transfer on S&G in major CVDs by reviewing the existing data that are relevant for patient treatment and identifying areas with a need for future studies. It focuses on issues that are both evidence based and meaningful to daily practice and have the potential to be included in future guidelines.

## Methods

The present materials have been gathered within the interdisciplinary EU-funded project EUGenMed (FP 7, www.eugenmed.eu/) by a group of experts specifically charged to develop a roadmap for the inclusion of gender aspects in European biomedical and health research. This position paper is part of this road map. The selection of covered topic, CVD, is based on the result of the EUGenMed process as described in the project outline and in the report of the kick-off conference held in April 2014 in Brussels, which is available at the project homepage (www.eugenmed.eu/). In particular, the experts decided to use CVD as an exemplary field to document that S&G differences are important for diagnosis, treatment, and research, recognizing that other fields—such as neurology, oncology, or others—deserve the same effort.

Legitimation of the writing group has been achieved by selecting this group of experts from a large set of European stakeholders in gender medicine at the EUGenMed kick-off conference in April 2014 in an open, transparent process as predefined in the EUGenMed project outline. Experts were invited to a workshop 1 on 'Gender aspects in clinical research and pharmacology', held in Berlin, 30 November to 2 December 2014 and developed together the present paper.

The group decided to focus on four major CVD areas—ischaemic heart disease (IHD), heart failure (HF), hypertension, and valvular heart disease—that are common in European populations. The group also decided to use the current ESC guidelines as a starting point for the definition of state-of-the-art knowledge and practice. The subsequently defined goal was to highlight S&G differences in the selected disease areas that are supported by evidence-based research findings and are relevant for patient care and to identify relevant missing aspects to be addressed in future research. For this purpose, systematic searches of the literature were performed using databases like PubMed and the GenderMedDB (http://gendermeddb.charite.de/), an international database of S&G-specific literature funded by the German Ministry of Education and Research.

## Ischaemic heart disease

Ischaemic heart disease is a common disease in all western societies. Ischaemic heart disease includes all damage due to ischaemia in the myocardium, regardless of whether the cause lies in the major coronary arteries, in the microcirculation, or in a supply/demand disbalance, whereas coronary artery disease (CAD) in general is understood as a diseases of the epicardial coronary arteries.[9]

### Epidemiology

Ischaemic heart disease develops on average 7–10 years later in women compared with men in most western societies. However, most likely due to unfavourable lifestyle changes over the past decades, manifestations of IHD in younger women are increasing.[10,11] Acute coronary syndromes (ACS), ST-elevation myocardial infarction (STEMI), or NSTEMI (Non-STEMI) occurs three to four times more often in men than in women below age 60, but after 75 years, women represent the majority of patients. Recently, the number of ACS in relatively younger women has increased in France and Germany for yet unknown reasons.[10,11]

Sex differences in risk factors for IHD have recently been discussed.[12] Premenopausal women have less often hypertension

and lower lipid levels than similarly aged men, whereas this reverses at older age. Diabetes emerged as a major risk factor that worsens the CAD outcome more in women than in men.[13] This applies not only to type 2 diabetes but also to young women with gestational diabetes or type 1 diabetes.[14,15] More comorbidities including obesity and inflammation as well as more unfavourable changes in coagulation and endothelial function may contribute to greater cardiometabolic risk factor load in diabetic women.[16] Women more often than men show isolated impaired glucose tolerance (IGT) that has a prevalence of up to 40% in elderly Europeans and already associates with higher cardiovascular risk. Detection of this prediabetic state and initiation of preventive measures are recommended.[17] Measurement of fasting plasma glucose and HbA1c combined or an oral glucose tolerance test (OGTT) to detect prevalent diabetes or IGT is recommended in all patients with CAD, but performance of OGTTs appears particularly important in women.

Depression and various forms of sustained mental stress (anxiety, anger, marital conflicts, work stress, etc.) have been acknowledged as aetiological and prognostic risk factors for CAD.[12] They increase the risk to develop CAD to similar degree in women and men. However, the prevalence is significantly higher in women, particularly in younger women, and this leads to a greater contribution to worse outcomes.[18,19] Multiple factors account for the impact of mental stress on increased risk for CAD—among them accumulation of behavioural risk factors and impairments in psychophysiological pathways with autonomic, endocrine, and inflammatory involvement in the first line. In the past, caution was warranted concerning psychological treatment options as several trials have shown that women with CAD and depression responded adversely to standardized depression interventions. However, emerging data now suggest that stress reduction programmes are safe and effective for women and men.[20,21]

## Clinical manifestations and pathophysiology

Acute coronary syndromes, STEMI, or NSTEMI without epicardial CAD or structural heart disease occur more frequently in women than in men.[9] In particular, younger women with ACS may present with open coronary arteries, with plaque erosions with distal embolization rather than plaque rupture with thrombus formation.[22,23] In NSTEMI women, it was recently demonstrated that coronary artery plaque area was associated with myocardial ischaemia independent of presence of coronary stenosis.[24] Not unfrequently, angina or ACS in women may be due to coronary microvascular disease, also called microvascular angina.[25,26] Women have more frequently components of pathological vasoreactivity, such as spasm and endothelial dysfunction (*Figure 2*).[27,28] An underdiagnosed cause of ACS is spontaneous coronary artery dissection (sCAD), which occurs predominantly in women, mostly between 45 and 60 years of age, preferentially in pregnancy or in the immediate postpartum period and may be caused by hormonal changes.[29] It may be related to fibromuscular dysplasia, inflammatory/immunologic diseases, and connective tissue diseases.[30] Estimated 8% of ACS in women but <1% in men are associated with the so-called Takotsubo syndrome (see below).[31,33]



**Figure 2** Development of ischaemic heart disease in women. The 'pink' zone reflects women at middle age, with a predominance of functional coronary artery disease and outward remodelling over obstructive CAD. CAD, coronary artery disease; ACS, acute coronary syndromes.

## Diagnosis

In ACS, patient's delay before seeking medical help is longer in women.[34,35] The lower awareness that women may also have a significant risk to develop ACS among patients and healthcare providers is an important contributor to this delay. It has recently been postulated that a sex-specific threshold for troponin I may improve the diagnostic accuracy of this most important laboratory test for diagnosis of AMI.[36] With the use of high-sensitive troponins, the diagnosis of MI is more often established in women.[37] Other biomarkers are also found to be sex specific. Proneurotensin was recently related to incident CVD only in women.[38] This area needs further investigations (*Table 1*).

The interpretation of non-invasive diagnostic testing is less reliable in women compared with men, especially in the age group below 60 years when the prevalence of obstructive CAD is still relatively low.[39] Non-specific electrocardiogram (ECG) changes at rest and a lower exercise capacity contribute to the lower sensitivity and specificity of non-invasive exercise testing in women.[40,41] As most exercise testing scores have been developed from populations that were composed primarily of men, only few scores have been designed especially for women.[42,43] The current ESC guidelines advise stress imaging techniques (e.g. SPECT, stress echocardiography) when available as first test of choice, with a preference for non-radiation diagnostics in younger women (*Table 2*).[39,44]

In the Swedish coronary angiography and angioplasty register (SCAAR), almost 80% of women with stable angina symptoms below age 60 had no visible coronary obstructions at angiography, compared with 40% of men.[45] Thus, primary diagnostic strategies in women searching for the classical 'male' pattern of obstructive CAD may be suboptimal, increasing the risk for procedural complications and leave vascular dysfunction or coronary microvessel disease in symptomatic women underdiagnosed.[46] In 2014, the American Heart Association launched evidence-based gender-specific guidelines for non-invasive testing that promote

**Table 1**    **Key sex and gender differences and recommendations for studies**

| | Key S&G differences | Key references for S&G | Recommendations for S&G sensitive studies |
|---|---|---|---|
| IHD | Distribution and impact of traditional risk factors for IHD (diabetes and stress), changing age distribution in patients with ACS | 10−12,18,19 | Mechanistic studies to understand greater relative increase in risk for IHD with diabetes for women; studies to analyse emerging changes in risk factor profiles; effect of stress reduction interventions |
| | Prevalence of CMD, sCAD, and Takotsubo (TTC) in women and men | 9,23,29,31−33 | Studies on mechanisms of vascular dysfunction in CMD; role of S&G differences in inflammation process in IHD; role of oestrogens in sCAD and TTC |
| | Sensitivity of diagnostic procedures of IHD | 40−43 | Identify optimal sex-, gender-, and age-sensitive strategies for the diagnosis of CMD |
| | Predictive value of hsTNI levels for MI and novel biomarkers (e.g. neurotensin) for IHD | 36−38 | Study whether the use of sex-specific diagnostic thresholds in hsTNI assays improves diagnosis of MI; study the contribution of neurotension to IHD prediction in women and men |
| | Outcomes after ACS and CABG | 55−57 | Prospective gender-sensitive outcome studies, focusing on gender-dependent risk factors |
| HF | Risk factors for HFpEF and prevalence of HFpEF | 86,87 | Test whether inflammation is a sex-specific and hormone-dependent risk factor in HFpEF; likewise for hyperglycaemia |
| | Ventricular remodelling in HFpEF | 85,87,90 | Test in valid cohort whether ventricular remodeling in women and men with HFpEF differs and whether this depends on risk factor profiles |
| | Patients with Takotsubo are characterized by low sex hormones and abnormal stress response | 31−33 | Test whether a decline in sex hormones leads to altered vascular function and altered stress response in male and female Takotsubo patients |
| | Response to CRT | 97,99,164 | Confirm S&G difference in outcome after CRT in prospective studies. Analyse mechanisms by MRT: more favorable remodeling or less fibrosis? |
| | Referral for cardiac transplantation | 104 | International multicentre prospective study on referral for heart transplantation, organ allocation, and survival |
| Hypertension | Ventricular adaptation to hypertension and patterns of regression | 110 | Study sex differences in myocardial remodelling and functional recovery under different drug therapies |
| AS | Myocardial adaptation and outcome after AV surgery | 121,122,129,130,133 | Study type of long-term remodelling after AS and its impact on postoperative (3 years) MACE and survival in women and men, and underlying mechanisms |
| | Myocardial adaptation and outcome after TAVI | 130−132,135 | Mechanistic study: why do women tolerate TAVI better than men? Impact of LVH type and of fibrosis (MRT) |
| MR | Atrial and LV diameters at comparable degrees of valvular dysfunction | 137,140,141 | Compare atrial and LV diameters, regurgitation fraction, and ventricular function in women and men with MR |
| | Outcome in MV surgery for MR | 141 | Test impact of sex-specific cut-off values for LV diameters on outcome after surgery in MR |
| Pharmacology | Serious adverse events due to drug interactions; outcomes under digitalis therapy for HF | 145,151 | Study whether numbers and causes of emergency hospitalizations for adverse drug effects differ in women and men; test sex differences in digitalis effects |

The suggested key facts, key references, and studies represent examples for worthwhile investigations on S&G differences. They do not claim to offer a comprehensive spectrum. CABG, coronary artery bypass surgery. ACS, Acute Coronary Syndrome; AS, Aortic Stenosis; AV, atrio-ventricular; CABG, Coronary Artery Bypass Graft Surgery; CMD, Coronary Microvascular Dysfunction; CRT, Cardiac Resynchronization Therapy; HF, Heart Failure; HFpEF, Heart failure with preserved ejection fraction; hsTnl, high-sensitive Troponin I; IHD, Ischemic Heart Disease; LV, Left Ventricular; LVH, Left Ventricular Hypertrophy; MACE, Major Adverse Cardiovascular Events; MI, myocardial infarction; MRT, Magnetic Resonance Tomography; MV, Mitral Valve; sCAD, Spontaneous Coronary Artery Dissection; TAVI, Transcatheter Aortic Valve Replacement; TTC, Takotsubo Cardiomyopathy.

selective functional and anatomic testing with non-invasive imaging techniques in women at intermediate risk.[39] These are helpful to avoid the still too large number of unnecessary and inconclusive angiograms in this patient population. Women at low IHD risk most often require no testing. Women at low−intermediate or intermediate IHD risk who can exercise adequately should be

**Table 2** Indications to stress testing/imaging or coronary computed tomography angiography in women with ischaemic symptoms

| Test | Exercise status | | ECG interpretable | | Pretest probability of IHD | | |
|---|---|---|---|---|---|---|---|
| | Able | Unable | Yes | No | Low | Intermediate | High |
| Exercise ECG | x | | x | | | x | |
| Exercise MPI | x | | | x | | x | x |
| Exercise Echo | x | | | x | | x | x |
| Pharmacological stress MPI | | x | Any | | | x | x |
| Pharmacological stress echo | | x | Any | | | x | x |
| Pharmacological stress CMR | | x | Any | | | x | x |
| CCTA | Any | | Any | | | (x) | x |

CCTA, coronary computed tomography angiography; CMR, cardiac magnetic resonance; IHD, ischaemic heart disease; MPI, myocardial perfusion imaging.

**Table 3** Cardiac resynchronization therapy studies that allow comparison of effects in women and men and most important parameters, list of references, and key parameters

| Trial | N women (proportion) | Treatment arms | NYHA class | LVEF | QRS | Primary endpoint | Gender difference in efficacy |
|---|---|---|---|---|---|---|---|
| COMPANION[96] | 501 (33%) | Medical therapy vs. CRT vs. CRT-D | III–IV | ≤35% | ≥120 ms | Death or hospitalization for any cause | Similar efficacy of CRT and CRT-D in both sexes |
| CARE-HF[162] | 216 (26%) | Medical therapy vs. CRT | III–IV | ≤35% | ≥120 ms | Death or hospitalization for major cardiovascular event | Similar efficacy of CRT in both sexes |
| REVERSE[163] | 131 (21%) | CRT on vs. CRT off | I–II | ≤40% | ≥120 ms | HF (clinical composite endpoint) | Similar efficacy of CRT in both sexes |
| MADIT-CRT[97] | 453 (25%) | CRT-D vs. ICD | I–II | ≤30% | ≥130 ms | Death or HF event | Significantly better efficacy of CRT-D in women than in men |
| RAFT[164] | 308 (17%) | CRT-D vs. ICD | II–III | ≤30% | ≥120 ms or paced ≥200 ms | Death or hospitalization for HF | Borderline better efficacy of CRT-D in women than in men |

CRT, cardiac resynchronization therapy; CRT-D, cardiac resynchronization therapy with defibrillator; ICD, implantable cardioverter-defibrillator; HF, heart failure; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; *N*, number of women enrolled.

referred to an Exercise Tolerance Test (ETT) first strategy. Coronary artery disease imaging is indicated for intermediate-risk or high-IHD-risk women with functional disability or an abnormal rest ECG. Diagnostic modalities for the assessment of coronary microvessel disease include measurement of coronary blood flow reserve by transthoracic echocardiography or positron emission tomography (PET)-CT perfusion or calculation of microcirculatory resistance indexes during coronary catheterization (coronary flow reserve).[25,47]

Women with recurrent chest pain syndromes and non-obstructive CAD need to be diagnosed and treated since they have a two-fold increased risk to develop obstructive CAD events in the next 5–8 years and have a four times higher risk for re-hospitalizations and recurrent angiograms than women without these symptoms.[48,49] Shaw *et al.* reported an expected consumption

of nearly $750 000 of cardiovascular healthcare resources related to the burden of ongoing symptoms and medications.[176]

## Treatment and outcomes

Treatment of stable CAD and ACS should be performed according to the current guidelines in both genders.[44] However, there is an ongoing debate whether outcomes are identical in women and men. In a large multicentre MI registry, female sex remained a strong independent predictor for re-hospitalization for ACS, but in other registries, the worse outcome in women was due to age and comorbidities.[50–52] Higher in-hospital mortality in women with ACS has been attributed to a longer patient's delay before admission, older age, a higher clustering of cardiovascular risk factors, lower use of invasive and medical treatment, and more bleeding complications after

interventions.[53] The risk for HF after MI in the Valsartan in Acute Myocardial Infarction Trial (VALIANT) was higher in women than in men.[54] In younger women (<60 years) with STEMI, adjusted in-hospital mortality rates are nearly twice as high as in similarly aged men.[55,56] In non-STEMI (NSTEMI) patients, a recent collaborative meta-analysis of three studies indicated that routine invasive strategy may not be preferred over a selective invasive strategy in women, in contrast to men.[57]

It is now well accepted that women derive the same benefits from percutaneous coronary intervention (PCI) as men. Previously, worse prognosis was attributed to smaller luminal diameters of the coronary arteries, risk factor profiles, more comorbidities, and referral bias in women. The Belgian Working Group on Interventional Cardiology (BWGIC) registry analysed a large cohort of 130 985 PCI procedures in Belgium, from January 2006 to February 2011. Female gender remained an independent predictor of mortality after multivariable adjustment.[58] In most studies with second-generation drug-eluting stents, S&G differences in the long-term outcome after PCI are not supported further. However, female gender remains an independent predictor for peri-procedural myocardial infarctions and major bleedings after PCI, which are associated with increased short-term morbidity and mortality.[59,60] Due to the relative higher contribution of functional coronary abnormalities and a more diffuse pattern of atherosclerosis in female patients with CAD, residual symptoms of angina are often present after ACS or coronary interventions.[61,62]

Using the transradial access for coronary interventions reduces the incidence of peri-procedural bleeding complications and improves the clinical outcome.[63] Because of the smaller size of the radial artery and its higher spasm tendency, this approach is more challenging in women. Female gender is not only an independent predictor for transradial approach failure but also for local bleedings after transradial coronary interventions.[64,65] However, long-term clinical outcomes appear to be similar to men.[66]

The use of fractional flow reserve-guided PCI has improved outcomes.[67] Fractional flow reserve values are found to be higher in women after correction for visually assessed coronary anatomic severity. This may be caused by the more frequent microvascular disease in women.[68] It is currently discussed whether gender-specific guidelines in interpreting fractional flow reserve measurements are warranted.[68,69]

Women also had higher mortality after elective coronary artery bypass surgery.[70] Major risk factors for women's mortality were low physical function, respiratory dysfunction, renal failure, and old age.[71] A recent study identified a significantly higher prevalence of diastolic dysfunction among females presenting for elective cardiac surgery and reported that women had a prolonged hospital stay.[72] Women have poorer health-related quality of life than men after coronary surgery.[73] Depression is a significant predictor of worse outcomes in women and men.[74]

Therapeutic options for coronary microvascular dysfunction are less well investigated than those for epicardial CAD; the efficacy of anti-anginal medications for symptom reduction is relatively poor, and optimal treatment options are lacking.[44,75] The presence of detectable peripheral coronary flow abnormalities in patients with microvascular dysfunction is associated with impaired prognosis in both men and women.[76,77] Therefore, this syndrome urgently needs more research.

# Heart failure and cardiomyopathies

## Epidemiology

Heart failure is one of the major health threats of western societies and affects up to 10% of the elderly, in absolute numbers more women than men.[78] In most studies and registries, women survive better than men and HF in women frequently occurs in older age and with less ischaemic aetiology than in men.[79,80] Few studies determined the true incidence of HF with preserved ejection fraction (HFpEF) and reduced ejection fraction (HFrEF) in women and men, but the available evidence suggests that the number of women with HFpEF is greater than the number of men, and HFrEF affects more men in Europe.[81] More HFrEF is due to MI in men longer life expectancy in women and greater prevalence of HFpEF in the older age groups may contribute to the higher prevalence of HFpEF in women. It is not clear how frequent a transition from HFpEF to HFrEF occurs in the population and if this is sex dependent. A transition from a hypertrophic to a dilated, hypocontractile phenotype has been described in detail in a case study of a women with hypertrophic cardiomyopathy (HCM).[82] More studies are needed here.

Dilated cardiomyopathy (DCM) and HCM are slightly more common in men compared with women, even though the autosomal underlying gene defects appear to be distributed equally among women and men.[83,84] It has been hypothesized that women are better protected against ventricular dilatation and systolic dysfunction than men.[85]

In contrast to HCM and DCM, the so-called Takotsubo cardiomyopathy (TTC) is a rare disease affecting predominantly women, ~70–90% women in most registries.[31,33] The latter manifests as an ACS or acute HF, often preceded by acute massive psychological or physical stress. The patients frequently recover with normalized EF. However, mortality is 8% and recurrence is estimated 5%.

## Clinical manifestations and pathophysiology

Sex differences were found in clinical characteristics and outcomes in elderly patients with HFpEF.[86] Ventricular remodelling under stress is also different. Combined effects of obesity and hypertension led to greater concentric hypertrophy in postmenopausal women, whereas in men, eccentric hypertrophy dominated.[87] The ventricular adaptation in HF should be considered in the context of normal physiology where women do have higher heart rates at rest and under exercise and, at different levels of stress, react with lower sympathetic response, greater vasodilation, and increased peripheral oxygen extraction, whereas men tend to use more the starling mechanism, increase stroke volume and blood pressures.[88] Smaller stroke volumes in women than in men were found in normal persons.[89] Women with HFpEF had smaller and stiffer hearts than men in a small single centre study.[85] Corroborating these findings, women with HF in the large Paramount trial had higher indexed left ventricular wall thicknesses and worse diastolic function than men.[90] Underlying mechanisms are not yet clear. A greater activation of profibrotic or proinflammatory pathways in men may contribute, as well as intrinsic sex differences in myocardial Ca handling or energy metabolism.[85,91] Paradigmatic changes in cardiac function in women and men are presented in *Figure 3*.

**Figure 3** Cardiac remodelling in women and men. Circles symbolize cross sections through a prototypic left ventricle in females (upper part, red) and in males (lower part, blue). The arrows symbolize the transition from a healthy to a diseased state. Female hearts are smaller in the healthy state. Following stress, e.g. exercise or pressure overload, females develop more frequently concentric hypertrophy with smaller internal cavity and relatively larger wall thickness than males, whereas males in general develop more readily eccentric hypertrophy, increased stroke volume, and dilatation.



**Figure 4** Donor−recipient relations in heart transplantation: fewer women than men undergo heart transplantation and women are more frequently donors than recipients. Example from a large German transplant centre, Deutsches Herzzentrum Berlin, based on 1263 cases from 1985 to 2012.

Oestrogen reduces catecholamine-induced vasoconstriction, promotes vasodilation, and may increase β2-adrenergic receptor responses.[88] A decrease in oestrogen levels may increase the sensitivity of the heart to circulating catecholamines. This is discussed as a contributing mechanism in HFpEF and in Takotsubo cardiomyopathy.

Major clinical manifestations in HF are not different in women and men.[80] Women exhibit a worse quality of life after diagnosis of HF and exhibit more frequently depression.[74,92] Because of the high prevalence of depression in women with HF, systematic screening may be considered.

In some but not all studies, women with HF had a lower prevalence of atrial fibrillation than men, which may be due to smaller left atrial size.[93] Since women with atrial fibrillation have a higher risk for stroke than men, for yet unknown reasons, female sex is included as an independent risk factor in the $CHA_2DS_2$-VASC score.[80]

## Diagnosis

Guideline-based diagnosis and therapy in HF does not differ between women and men. However, diagnosis was less frequently based on objective diagnostic tests in women.[94] In the Euro Heart Survey, echocardiography was used less frequently in women.[81,95] Physicians should be informed about this potential bias in order to reduce it.

## Treatment and outcomes

### Cardiac resynchronization therapy

Cardiac resynchronization therapy (CRT) improves survival and quality of life in patients with HF and conduction delay.[96,97] Women are poorly represented in clinical trials (20% of enrollees) that result in a selection bias in current guidelines.[98] In some studies, women experienced more benefit than men from resynchronization therapy (*Table 3*). Women but not men had a benefit independently of the QRS duration and baseline characteristics.[97,99] A recent FDA meta-analysis of three major clinical trials with mild HF confirmed that the indication for CRT in women seems to be at a shorter QRS duration.[100,101] Results from the Swedish Heart Failure Registry showed that CRT was equally underutilized in both genders and QRS prolongation was not more harmful in women than in men.[102]

### Ventricular assist device

Registry analysis of the International Society of Heart and Lung Transplantation (ISHLT) repeatedly showed a severe survival deficit in women after device implantation. This was frequently attributed to differences in disease states and types of devices used. Analysis of 139 patients (including 24 women) before (115/24) and after (24/24) propensity matching all treated with HeartMate II und HeartWare allowed for a comparison of women and men independent of device type.[103] This study indicated a survival benefit for men in the overall sample, whereas no difference was found in the matched patient group. Analysis of clinical data showed that women were referred in more severe disease state what explains survival disadvantages before and the disappearance after adjustment.

### Heart transplantation

Fewer women than men undergo heart transplantation and men are more frequently recipients, whereas women are more frequently donors (*Figure 4*). In a data set of 698 consecutive patients with idiopathic non-ischaemic DCM referred for heart transplantation to the German Heart Institute, only 15.6% were women, suggesting a referral bias against women. Women were more frequently in New York Heart Association functional class III−IV than men, had lower exercise tolerance, respiratory efficiency, and kidney function. Women referred for transplantation also had significantly frequently less diabetes than men, even though women in HF populations have the same diabetes rate as men. Thus, women were referred at a more advanced disease state and relative contraindications such

as diabetes appear to be taken more seriously in women.[104] However, the low number of women in this study may limit conclusions. An international multicentre prospective study on referral for heart transplantation, organ allocation, and survival appears mandatory.

# Hypertension

## Epidemiology

In European countries and the USA, one in three adults presents with arterial hypertension based on current guideline definitions.[105,106] Noteworthy are the differences between women and men in younger age groups (18 and 29 years), showing only a prevalence of 1.3% in women vs. 8.5% in men and 7.3% in women vs. 15.8% in men in the group between 30 and 44 years.[105] In contrast, hypertension is more common in women than in men in the elderly population.

## Clinical manifestations and pathophysiology

No sex differences in clinical manifestations of hypertension outside of pregnancy-related hypertension have been described. A number of S&G differences in the pathophysiology of hypertension have been reported, mainly related to S&G differences in the renin−angiotensin system and in the bradykinin and NO system. However, none of those have had consequences for medical therapy so far. Disturbances in sexual hormone production as they occur in the polycystic ovarian syndrome or during postmenopausal decline in oestrogen levels have been associated with hypertension in women.[107,108]

## Diagnosis

In accordance to current guidelines, no differences between men and women have been documented regarding diagnostic approaches for hypertension.[109] Female sex stands among the factors associated with a higher prevalence of white coat hypertension, whereas male sex is related to increased prevalence of masked hypertension.[109]

## Treatment and outcomes

Hypertensive left ventricular hypertrophy is more difficult to treat in women, and residual hypertrophy is more common than in men despite systematic antihypertensive treatment.[110] Hypertensive women sustain higher left ventricular ejection fraction and other measures of systolic function.[110] Nevertheless, women exhibit less regression under medical therapy and they have an estimated three-fold higher risk for developing congestive HF or stroke compared with men.[111,112] Hypertensive women develop more vascular and myocardial stiffness than men at old age, and more often have isolated systolic hypertension, reflecting aortic stiffness.[113] This is closely associated with their higher prevalence of strokes and HFpEF.[114]

# Aortic valve stenosis

## Epidemiology

Aortic stenosis (AS) is the most common valvular heart disease requiring valve replacement. In the European populations, the prevalence is up to 5% among subjects aged 70−79 years and up to 10%

among subjects >80 years of age. Aortic stenosis due to a congenital bicuspid valve is three times more common among men than women,[115] while degenerative AS is more common among women with a women : men ratio of 1 : 0.76.[116]

## Clinical manifestations and pathophysiology

In general, the clinical presentation of patients with AS does not differ between women and men. As a consequence of AS progression, leading to increasing pressure overload on the left ventricle, women develop more concentric hypertrophy with smaller internal cavity and relatively larger wall thickness than men.[117,118] Women, independently of left ventricular size, also preserve better ejection fraction and myocardial contractility than men during progression of AS.[119,120] Lower myocardial function was found in men compared with women with AS in the SEAS and in a smaller study.[117] This may be due to the greater amount of fibrosis that is found in male in comparison with female hearts of patients undergoing aortic valve surgery.[121,122] Men exhibit more excentric hypertrophy at aortic valve surgery and show less regression of myocardial hypertrophy than women after surgery. More longitudinal studies are needed to understand the sex differences in remodelling and their clinical consequences.

## Diagnosis

The diagnostic strategy in AS does not differ between women and men. However, calcification measured by multidetector computer tomography (Agatston score) is more pronounced in men than in women independent of the severity of the AS.[123] Recently, sex-specific cut-off values for Agatston score identifying severe AS were documented.[124] In subjects with small body size, frequently women, indexation of the valve opening area for body surface area avoids overestimation of AS severity and is recommended in the current guidelines.[125] However, in patients with mild AS and a small aortic root dimension, the effective aortic valve area indexed for body surface area may overestimate the actual AS severity by 30% if not adjusted for post-stenotic pressure recovery. A small aortic root is particularly common among elderly women, and unnecessary surgery in these is avoided by proper indexation.[126]

## Treatment and outcomes

It is well recognized that perioperative mortality and complications are higher in women than in men undergoing surgical aortic valve replacement.[125] For AS patients at high operative risk, transcatheter aortic valve implantation (TAVI) is an increasingly recognized therapeutic option.[127,128] Current data argue for an outcome benefit in women treated with TAVI,[129] especially, among patients suitable for transfemoral access. Whereas procedural device success rates are similar between women and men after TAVI, short- and mid-term survival is greater in women (*Figure 5*).[130−132] In TAVI patients with severe left ventricular hypertrophy in the PARTNER trial, post-operative hypertrophy regression was more pronounced in women and associated with a 50% reduction in new hospitalizations, particularly for HF.[133] Interestingly, outcome benefit in women is observed despite more procedure-related complications, such as major vascular complications (related to smaller vessel size), bleedings, or rarely occurring coronary obstructions.[131,132,134] It remains

**Figure 5** Gender differences in TAVI outcome. Metaanalysis of published trials with the end point total mortality during follow-up.[132]

to be elucidated whether this advantage is merely associated with differences in baseline characteristics or whether it reflects a better reversibility of myocardial hypertrophy in women.[135,136] Stroke rates are not different between genders.

# Mitral valve prolapse and mitral regurgitation

## Epidemiology

In general populations, mitral valve prolapse is found in 2.5–4% more frequently in women than in men, and more often involves the anterior or both leaflets, while men have more often posterior prolapse and flail leaflets.[137] The lifetime risk for need of mitral valve surgery is 4% in men and 1.5% in women with mitral valve prolapse.[138]

## Diagnosis

Current guidelines do not include sex-specific recommendations for indications in mitral valve surgery.[125,139] For asymptomatic severe mitral regurgitation, an end-systolic left ventricular dimension >40 mm (>45 mm in European guidelines) and an ejection fraction <60% are criteria suggesting referral for surgical treatment.[125,139] Since women normally have smaller hearts and higher ejection fractions, these criteria may lead to underdiagnosis of asymptomatic severe mitral regurgitation in women, delayed surgical treatment, and lack of postoperative normalization of life expectancy.[140]

## Treatment and outcomes

Among patients with severe regurgitation, women were 20% less likely than men to undergo mitral valve surgery in a retrospective

study from the Mayo clinic.[137] This may be related to the smaller left ventricular and atrial dimensions in women, often not reaching the classic unadjusted dimensions used for surgical indication in severe mitral regurgitation.

From a review of >180 000 Medicare beneficiaries, women with mitral regurgitation undergoing mitral valve surgery had lower survival than men, independent of type of valve surgery (mitral repair or replacement, respectively).[141] The lower survival was attributed to higher preoperative risk, in particular HF, atrial fibrillation, and respiratory failure, reflecting a more longstanding and severe regurgitation at the time of referral for surgical treatment. The authors suggested a physician referral bias, but women seeking medical care at a later stage may also have contributed to a more advanced stage of illness before consultation with a physician.

# Pharmacological therapy

## Pharmacokinetics

Sex and gender differences in pharmacokinetics are caused by sex-specific oral bioavailability, amount and distribution of body fat, clearance, volume distribution, absorption, plasma protein binding, urinary excretion, and metabolism. A typical example of cardiac drugs showing overall systemic sex-specific differences in pharmacokinetics is β-blockers (for example metoprolol and propranolol).[142] A lower distribution volume for β-blockers in women, related to the difference in body dimension/composition, could potentially lead to the lower clearance rate of those drugs that is frequently observed in women.[143] Furthermore, the clearance of those β-blockers that are metabolized by the cytochrome P isoenzyme

**Table 4** Sex differences in drug effects (adapted from Regitz-Zagrosek and Seeland[159])

| Treatment | Sex-specific drug effects | References |
|---|---|---|
| Digitalis | Higher risk for death among women with HF compared with placebo | 146 |
| | Reduced distribution volume, lower drug elimination in women | 165 |
| Antiarrhythmics | Drug-induced Torsades de pointes (TdP) observed predominantly in women | 166−170 |
| Anticoagulants and ASA | Haemorrhage incidence increased in women | 171 |
| | Haematuria, haemoptysis, and intracranial bleeding incidence increased in men | 172 |
| | Higher benefit observed in women (Vitamin K antagonists, Fondaparinux) | 173,174 |
| | Increased bleeding risk observed in women (Bivalirudin) | 175 |

ASA, Acetylsalicylic Acid.

CYP2D6 is markedly higher in men, and increased plasma levels are associated with more adverse effects in women.[143,144]

## Pharmacodynamics

Sex differences in drug effects are most commonly described for digitalis, antiarrhythmics, and anticoagulants (*Table 4*), but sex differences do also exist for other drugs. Mortality under digitalis treatment was higher in women than in men in a *post hoc* analysis of the largest randomized prospective trial on digitalis in HF.[145] Underlying reasons are unclear but may be associated with higher blood concentrations in women due to hormonal factors or sex differences in renal function.[146] They may, however, also be related to sex differences in cardiac ion channel function. Testosterone and oestrogen affect several cardiac ion channels.[147,148] Women have a longer repolarization phase resulting in longer QT duration on the ECG. Therefore, female sex is a potential risk factor for fatal ventricular tachycardia type 'Torsade de Pointes', which can be induced by, for example, antiarrhythmic, antidepressive, and antiallergic medications.

The efficacy of aspirin in the primary prevention of MI and stroke differs in women and men, with greater protection from a first MI in men and from stroke in women. In primary prevention, there are reports that aspirin protects more against stroke in women and more against MI in men.[149] The reason is unclear. It could be a matter of prevalence of the diseases in women and men at different ages or an interaction of hormonal state with age-specific disease mechanisms. In secondary prevention, however, the effects of aspirin are the same in both sexes and at similar ages.

## Sex and gender differences in cardiovascular drug safety

Sixty percentage of all patients admitted to the hospital for adverse drug events are women.[150−154] Predominantly women display dose-related adverse drug events[154] that may be due to the fact that risk factors for adverse drug events, such as polytherapy, aging, and depression, are more frequent in women than in men.[155] Furthermore, doses of drugs are frequently not well adapted to the smaller body size, higher body fat content, or hepatic metabolism in women, or lower kidney function in elderly women. As discussed, women with HF have a higher rate of adverse drug events than men

especially with diuretics, anticoagulants, digoxin, and Angiotensin Converting Enzyme Inhibitors.[156] In conclusion, adverse drug events represent a source of greater health concern in women than in men and, therefore, need to be investigated further in more depth. Reducing the number and severity of adverse drug events in women should be a priority because decreasing the number of adverse drug events will increase the social and economic benefits of pharmacotherapy.[157] The US GAO report from 2006 describes that six drugs were withdrawn from market for adverse effects and that these posed greater health risks to women than men. A recent analysis suggests that costs for a new molecular entity to launch are in the mean $1.78 billion.[158] Thus, preventing some of the drug withdrawals by better targeting drugs and doses for women could have saved several billions.

# Consequences, needs, and implementation

## Consequences

We described a number of S&G differences in CVD (supplementary materials), but these differences are not well known in the medical community and therefore do not have major impact in medical practice so far. This lack of knowledge is costly. If coronary angiography is used as an early diagnostic procedure in women with angina like syndromes, that are at low or intermediate risk for developing CAD, far too many women will undergo this expensive and invasive procedure without a positive result.[45] In valvular heart disease, consideration of gender may be helpful to decide on most efficient treatment strategies, i.e. the use of TAVI or conventional surgery. The same may apply for decisions on resynchronization therapy that is less frequently used in women than in men but has a greater benefit in women and may help to prevent more expensive consequences of HF. In contrast, implanted defibrillators may be more efficient in men. Thus, gendered approaches may lead to a more specific and effective use of resources.[159]

## Needs assessment

In order to include gender into decision algorithms, we still need more evidence-based data. This requires gender-sensitive study

strategies. Cardiovascular outcome trials must be designed with an adequate statistical power to obtain meaningful results for women and men. This is a challenge for study planning, since we must include knowledge on estimated event rates in specific population groups as well as knowledge on gender-specific risk factors for developing CVD and outcomes during the design process. We must use strategies like potentially oversampling one sex, pre-stratification, prospective planning for meta-analyses based on segregated patient data,[160] studying effect of interactions of risk factors with multilevel Cox regression models,[50] or plan intersectional designs for relevant covariates from the beginning[161] to avoid inefficient data gathering, i.e. accumulation of data that cannot be analysed by lack of power. Such studies may appear more costly at first glance; however, since they give much more answers than a gender-blind design, they will be more conclusive in the long run and reduce the economic and indirect costs of post-marketing withdrawal as discussed above. Withdrawal of drugs from market for adverse effects has to be estimated with $1.78 billion,[158] and six from eight drugs withdrawn from the market and included in the GAO report had more adverse effects in women than in men.

## Implementation

The cardiology societies are at the forefront of implementing the new gender-sensitive findings into the research and healthcare strategies. They have already accumulated a large number of knowledge in S&G differences and they are in a position to communicate this at their congresses and to organize sessions on S&G issues. They are in charge of integrating new knowledge into guidelines. They are frequently involved in designing registries and clinical studies and it should be mandatory for them to assure that gender-sensitive data are collected and distributed. They can organize training courses that are badly needed because today's practitioners have not been trained in gender medicine. For active clinical and basic research, a number of tools have been developed that can facilitate gendered analysis (http://genderedinnovations.stanford.edu/). The willingness of the funding agencies is needed to include S&G into preclinical research and clinical studies. National Institutes of Health published on 9 June 2015 a notice announcing that sex has to be included into all animal research and human studies or it has to be justified why this is not the case (Notice Number: NOT-OD-15-102). Likewise, journal editors should require information on S&G or an explanation why it is not important in all studies submitted for publication. Neglecting S&G issues without proper reasoning and explanations prevents proper validation of research findings, limits reproducibility, and will not lead to high-quality results. Last, policy makers must be convinced that S&G issues improve the quality of biomedical research and health care and must also be willing to mandate S&G issues into research and medical practice.

In conclusion, more precise algorithms for gendered approaches may lead to a more specific and effective use of resources in CV therapy. For this purpose, more evidence-based clinical data are required. For successful implementation, the support of cardiology societies, active researchers, funding organizations, journal editors, and policy makers is needed.

## Author's contributions

V.R.-Z. designed the study; V.R.-Z. handled funding and supervision; V.R.-Z., S.O.-P., E.B.-P., F.F., E.G., A.F.-L., A.M., A.K.-W., D.K., U.K., K.H.L., K.S.-G., and V.S. acquired the data; V.R.-Z. conceived and designed the research; V.R.-Z., S.O.-P., E.B.-P., F.F., E.G., A.F.-L., A.M., A.K.-W., D.K., U.K., K.H.L., K.S.-G., and V.S. drafted the manuscript; S.O.-P., E.B.-P., F.F., E.G., A.F.-L., A.M., A.K.-W., D.K., U.K., K.H.L., K.S.-G., and V.S. made critical revision of the manuscript for key intellectual content.

## Supplementary material

Supplementary material is available at *European Heart Journal* online.

### References

1. Oertelt-Prigione S, Regitz-Zagrosek V. *Sex and Gender Aspects in Clinical Medicine*. London: Springer Verlag; 2011.
2. Schenck-Gustafsson K, DeCola PR, Pfaff DW, Pisetsky DS. *Handbook of Clinical Gender in Medicine*. Basel: Karger; 2012.
3. Legato M. *Principles of Gender-Specific Medicine*. 2nd ed. Amsterdam/Boston: Elsevier; 2010.
4. United States General Accounting Office. *Drug Safety: Most Drugs Withdrawn in Recent Years had Greater Health Risks for Women*. Washington, DC: Government Publishing Office; 2001.
5. Clayton JA, Collins FS. Policy: NIH to balance sex in cell and animal studies. *Nature* 2014;**509**:282–283.
6. Wizemann TM, Pardue ML. *Exploring the Biological Contributions to Human Health: Does Sex Matter?* Washington, DC: National Academies Press; 2001.
7. National Research Council. *Women's Health Research: Progress, Pitfalls, and Promise*. Washington, DC: The National Academies Press; 2010.
8. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetiere P, Jousilahti P, Keil U, Njolstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham IM, Score Project Group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. *Eur Heart J* 2003;**24**:987–1003.
9. Shaw LJ, Bugiardini R, Merz CN. Women and ischemic heart disease: evolving knowledge. *J Am Coll Cardiol* 2009;**54**:1561–1575.
10. Ford ES, Capewell S. Coronary heart disease mortality among young adults in the U.S. from 1980 through 2002: concealed leveling of mortality rates. *J Am Coll Cardiol* 2007;**50**:2128–2132.
11. Puymirat E, Simon T, Steg PG, Schiele F, Gueret P, Blanchard D, Khalife K, Goldstein P, Cattan S, Vaur L, Cambou JP, Ferrieres J, Danchin N, Usik Usic Investigators, Fast MI Investigators. Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction. *JAMA* 2012;**308**:998–1006.
12. Vaccarino V, Badimon L, Corti R, de Wit C, Dorobantu M, Hall A, Koller A, Marzilli M, Pries A, Bugiardini R, Working Group on Coronary Pathophysiology and Microcirculation. Ischaemic heart disease in women: are there sex differences in pathophysiology and risk factors? Position paper from the working group on

coronary pathophysiology and microcirculation of the European Society of Cardiology. *Cardiovasc Res* 2011;**90**:9–17.

13. Barrett-Connor EL, Cohn BA, Wingard DL, Edelstein SL. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. *JAMA* 1991;**265**:627–631.

14. Huxley RR, Peters SA, Mishra GD, Woodward M. Risk of all-cause mortality and vascular events in women versus men with type 1 diabetes: a systematic review and meta-analysis. *Lancet Diabetes Endocrinol* 2015;**3**:198–206.

15. Kaul P, Savu A, Nerenberg KA, Donovan LE, Chik CL, Ryan EA, Johnson JA. Impact of gestational diabetes mellitus and high maternal weight on the development of diabetes, hypertension and cardiovascular disease: a population-level analysis. *Diabet Med* 2015;**32**:164–173.

16. Donahue RP, Rejman K, Rafalson LB, Dmochowski J, Stranges S, Trevisan M. Sex differences in endothelial function markers before conversion to pre-diabetes: does the clock start ticking earlier among women? The Western New York Study. *Diabetes Care* 2007;**30**:354–359.

17. Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes HP, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J, Patrono C, Seferovic P, Uva MS, Taskinen MR, Tendera M, Tuomilehto J, Valensi P, Zamorano JL, ESC Committee for Practice Guidelines, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Document R, De Backer G, Sirnes PA, Ezquerra EA, Avogaro A, Badimon L, Baranova E, Baumgartner H, Betteridge J, Ceriello A, Fagard R, Funck-Brentano C, Gulba DC, Hasdai D, Hoes AW, Kjekshus JK, Knuuti J, Kolh P, Lev E, Mueller C, Neyses L, Nilsson PM, Perk J, Ponikowski P, Reiner Z, Sattar N, Schachinger V, Scheen A, Schirmer H, Stromberg A, Sudzhaeva S, Tamargo JL, Viigimaa M, Vlachopoulos C, Xuereb RG. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). *Eur Heart J* 2013;**34**:3035–3087.

18. Parashar S, Rumsfeld JS, Reid KJ, Buchanan D, Dawood N, Khizer S, Lichtman J, Vaccarino V, Premier Registry Investigators. Impact of depression on sex differences in outcome after myocardial infarction. *Circ Cardiovasc Qual Outcomes* 2009;**2**:33–40.

19. Xu X, Bao H, Strait K, Spertus JA, Lichtman JH, D'Onofrio G, Spatz E, Bucholz EM, Geda M, Lorenze NP, Bueno H, Beltrame JF, Krumholz HM. Sex differences in perceived stress and early recovery in young and middle-aged patients with acute myocardial infarction. *Circulation* 2015;**131**:614–623.

20. Huffman JC, Mastromauro CA, Sowden G, Fricchione GL, Healy BC, Januzzi JL. Impact of a depression care management program for hospitalized cardiac patients. *Circ Cardiovasc Qual Outcomes* 2011;**4**:198–205.

21. Orth-Gomer K, Schneiderman N, Wang HX, Walldin C, Blom M, Jernberg T. Stress reduction prolongs life in women with coronary disease: the Stockholm Women's Intervention Trial for Coronary Heart Disease (SWITCHD). *Circ Cardiovasc Qual Outcomes* 2009;**2**:25–32.

22. Yahagi K, Davis HR, Arbustini E, Virmani R. Sex differences in coronary artery disease: pathological observations. *Atherosclerosis* 2015;**239**:260–267.

23. Reynolds HR, Srichai MB, Iqbal SN, Slater JN, Mancini GB, Feit F, Pena-Sing I, Axel L, Attubato MJ, Yatskar L, Kalhorn RT, Wood DA, Lobach IV, Hochman JS. Mechanisms of myocardial infarction in women without angiographically obstructive coronary artery disease. *Circulation* 2011;**124**:1414–1425.

24. Eskerud I, Gerdts E, Nordrehaug JE, Lonnebakken MT. Global coronary artery plaque area is associated with myocardial hypoperfusion in women with non-ST elevation myocardial infarction. *J Womens Health (Larchmt)* 2015;**24**:367–373.

25. Camici PG, d'Amati G, Rimoldi O. Coronary microvascular dysfunction: mechanisms and functional assessment. *Nat Rev Cardiol* 2015;**12**:48–62.

26. Herrmann J, Kaski JC, Lerman A. Coronary microvascular dysfunction in the clinical setting: from mystery to reality. *Eur Heart J* 2012;**33**:2771–2782b.

27. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Joint ESC/Accf/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction, Katus HA, Lindahl B, Morrow DA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasche P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S. Third universal definition of myocardial infarction. *Circulation* 2012;**126**:2020–2035.

28. Johnston N, Jonelid B, Christersson C, Kero T, Renlund H, Schenck-Gustafsson K, Lagerqvist B. Effect of gender on patients with ST-elevation and non-ST-elevation myocardial infarction without obstructive coronary artery disease. *Am J Cardiol* 2015;**115**:1661–1666.

29. Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, Cifkova R, Ferreira R, Foidart JM, Gibbs JS, Gohlke-Baerwolf C, Gorenek B, Iung B, Kirby M, Maas AH, Morais J, Nihoyannopoulos P, Pieper PG, Presbitero P, Roos-Hesselink JW, Schaufelberger M, Seeland U, Torracca L, ESC Committee for Practice Guidelines, European Society of Gynecology, Association for European Paediatric Cardiology, German Society for Gender Medicine. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). *Eur Heart J* 2011;**32**:3147–3197.

30. Saw J, Aymong E, Sedlak T, Buller CE, Starovoytov A, Ricci D, Robinson S, Vuurmans T, Gao M, Humphries K, Mancini GB. Spontaneous coronary artery dissection: association with predisposing arteriopathies and precipitating stressors and cardiovascular outcomes. *Circ Cardiovasc Interv* 2014;**7**:645–655.

31. Komamura K, Fukui M, Iwasaku T, Hirotani S, Masuyama T. Takotsubo cardiomyopathy: pathophysiology, diagnosis and treatment. *World J Cardiol* 2014;**6**:602–609.

32. Parodi G, Del Pace S, Carrabba N, Salvadori C, Memisha G, Simonetti I, Antoniucci D, Gensini GF. Incidence, clinical findings, and outcome of women with left ventricular apical ballooning syndrome. *Am J Cardiol* 2007;**99**:182–185.

33. Sharkey SW, Maron BJ. Epidemiology and clinical profile of Takotsubo cardiomyopathy. *Circ J* 2014;**78**:2119–2128.

34. Diercks DB, Owen KP, Kontos MC, Blomkalns A, Chen AY, Miller C, Wiviott S, Peterson ED. Gender differences in time to presentation for myocardial infarction before and after a national women's cardiovascular awareness campaign: a temporal analysis from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress ADverse Outcomes with Early Implementation (CRUSADE) and the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network-Get with the Guidelines (NCDR ACTION Registry-GWTG). *Am Heart J* 2010;**160**:80–87.e3.

35. Kaul P, Armstrong PW, Sookram S, Leung BK, Brass N, Welsh RC. Temporal trends in patient and treatment delay among men and women presenting with ST-elevation myocardial infarction. *Am Heart J* 2011;**161**:91–97.

36. Huynh K. Biomarkers: high-sensitivity troponin assays for the diagnosis of AMI-sex-specific differences? *Nat Rev Cardiol* 2015;**12**:129.

37. Shah AS, Griffiths M, Lee KK, McAllister DA, Hunter AL, Ferry AV, Cruikshank A, Reid A, Stoddart M, Strachan F, Walker S, Collinson PO, Apple FS, Gray AJ, Fox KA, Newby DE, Mills NL. High sensitivity cardiac troponin and the under-diagnosis of myocardial infarction in women: prospective cohort study. *BMJ* 2015;**350**:g7873.

38. Melander O, Maisel AS, Almgren P, Manjer J, Belting M, Hedblad B, Engstrom G, Kilger U, Nilsson P, Bergmann A, Orho-Melander M. Plasma proneurotensin and incidence of diabetes, cardiovascular disease, breast cancer, and mortality. *JAMA* 2012;**308**:1469–1475.

39. Mieres JH, Gulati M, Bairey Merz N, Berman DS, Gerber TC, Hayes SN, Kramer CM, Min JK, Newby LK, Nixon JV, Srichai MB, Pellikka PA, Redberg RF, Wenger NK, Shaw LJ, American Heart Association Cardiac Imaging Committee of the Council on Clinical Cardiology, Cardiovascular Imaging and Intervention Committee of the Council on Cardiovascular Radiology and Intervention. Role of noninvasive testing in the clinical evaluation of women with suspected ischemic heart disease: a consensus statement from the American Heart Association. *Circulation* 2014;**130**:350–379.

40. Douglas PS, Ginsburg GS. The evaluation of chest pain in women. *N Engl J Med* 1996;**334**:1311–1315.

41. Mieres JH, Shaw LJ, Arai A, Budoff MJ, Flamm SD, Hundley WG, Marwick TH, Mosca L, Patel AR, Quinones MA, Redberg RF, Taubert KA, Taylor AJ, Thomas GS, Wenger NK, Cardiac Imaging Committee, Council on Clinical Cardiology and the Cardiovascular Imaging and Intervention Committee, Council on Cardiovascular Radiology and Intervention, American Heart Association. Role of noninvasive testing in the clinical evaluation of women with suspected coronary artery disease: consensus statement from the Cardiac Imaging Committee, Council on Clinical Cardiology, and the Cardiovascular Imaging and Intervention Committee, Council on Cardiovascular Radiology and Intervention, American Heart Association. *Circulation* 2005;**111**:682–696.

42. Gulati M, Black HR, Shaw LJ, Arnsdorf MF, Merz CN, Lauer MS, Marwick TH, Pandey DK, Wicklund RH, Thisted RA. The prognostic value of a nomogram for exercise capacity in women. *N Engl J Med* 2005;**353**:468–475.

43. Morise AP, Lauer MS, Froelicher VF. Development and validation of a simple exercise test score for use in women with symptoms of suspected coronary artery disease. *Am Heart J* 2002;**144**:818–825.

44. Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK,

Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabate M, Senior R, Taggart DP, van der Wall EE, Vrints CJ, ESC Committee for Practice Guidelines, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Document R, Knuuti J, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol C, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Hasdai D, Husted S, James SK, Kervinen K, Kolh P, Kristensen SD, Lancellotti P, Maggioni AP, Piepoli MF, Pries AR, Romeo F, Ryden L, Simoons ML, Sirnes PA, Steg PG, Timmis A, Wijns W, Windecker S, Yildirir A, Zamorano JL. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. *Eur Heart J* 2013;**34**:2949–3003.

45. Johnston N, Schenck-Gustafsson K, Lagerqvist B. Are we using cardiovascular medications and coronary angiography appropriately in men and women with chest pain? *Eur Heart J* 2011;**32**:1331–1336.

46. Flammer AJ, Anderson T, Celermajer DS, Creager MA, Deanfield J, Ganz P, Hamburg NM, Luscher TF, Shechter M, Taddei S, Vita JA, Lerman A. The assessment of endothelial function: from research into clinical practice. *Circulation* 2012;**126**:753–767.

47. Knaapen P, Camici PG, Marques KM, Nijveldt R, Bax JJ, Westerhof N, Gotte MJ, Jerosch-Herold M, Schelbert HR, Lammertsma AA, van Rossum AC. Coronary microvascular resistance: methods for its quantification in humans. *Basic Res Cardiol* 2009;**104**:485–498.

48. Robinson JG, Wallace R, Limacher M, Ren H, Cochrane B, Wassertheil-Smoller S, Ockene JK, Blanchette PL, Ko MG. Cardiovascular risk in women with non-specific chest pain (from the Women's Health Initiative Hormone Trials). *Am J Cardiol* 2008;**102**:693–699.

49. Jespersen L, Abildstrom SZ, Hvelplund A, Madsen JK, Galatius S, Pedersen F, Hojberg S, Prescott E. Burden of hospital admission and repeat angiography in angina pectoris patients with and without coronary artery disease: a registry-based cohort study. *PLoS One* 2014;**9**:e93170.

50. van Loo HM, van den Heuvel ER, Schoevers RA, Anselmino M, Carney RM, Denollet J, Doyle F, Freedland KE, Grace SL, Hosseini SH, Parakh K, Pilote L, Rafanelli C, Roest AM, Sato H, Steeds RP, Kessler RC, de Jonge P. Sex dependent risk factors for mortality after myocardial infarction: individual patient data meta-analysis. *BMC Med* 2014;**12**:242.

51. Kyto V, Sipila J, Rautava P. Gender and in-hospital mortality of ST-segment elevation myocardial infarction (from a multihospital nationwide registry study of 31,689 patients). *Am J Cardiol* 2015;**115**:303–306.

52. Arnold SV, Smolderen KG, Kennedy KF, Li Y, Shore S, Stolker JM, Wang TY, Jones PG, Zhao Z, Spertus JA. Risk factors for rehospitalization for acute coronary syndromes and unplanned revascularization following acute myocardial infarction. *J Am Heart Assoc* 2015;**4**:e001352.

53. Berger JS, Elliott L, Gallup D, Roe M, Granger CB, Armstrong PW, Simes RJ, White HD, Van de Werf F, Topol EJ, Hochman JS, Newby LK, Harrington RA, Califf RM, Becker RC, Douglas PS. Sex differences in mortality following acute coronary syndromes. *JAMA* 2009;**302**:874–882.

54. Lam CS, McEntegart M, Claggett B, Liu J, Skali H, Lewis E, Kober L, Rouleau J, Velazquez E, Califf R, McMurray JJ, Pfeffer M, Solomon S. Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). *Eur J Heart Fail* 2015;**17**:301–312.

55. Champney KP, Frederick PD, Bueno H, Parashar S, Foody J, Merz CN, Canto JG, Lichtman JH, Vaccarino V, NRMI Investigators. The joint contribution of sex, age and type of myocardial infarction on hospital mortality following acute myocardial infarction. *Heart* 2009;**95**:895–899.

56. Otten AM, Maas AH, Ottervanger JP, Kloosterman A, van 't Hof AW, Dambrink JH, Gosselink AT, Hoorntje JC, Suryapranata H, de Boer MJ, Zwolle Myocardial Infarction study Group. Is the difference in outcome between men and women treated by primary percutaneous coronary intervention age dependent? Gender difference in STEMI stratified on age. *Eur Heart J Acute Cardiovasc Care* 2013;**2**:334–341.

57. Alfredsson J, Clayton T, Damman P, Fox KA, Fredriksson M, Lagerqvist B, Wallentin L, de Winter RJ, Swahn E. Impact of an invasive strategy on 5 years outcome in men and women with non-ST-segment elevation acute coronary syndromes. *Am Heart J* 2014;**168**:522–529.

58. Lempereur M, Magne J, Cornelis K, Hanet C, Taeymans Y, Vrolix M, Legrand V. Impact of gender difference in hospital outcomes following percutaneous coronary intervention. Results of the Belgian Working Group on Interventional Cardiology (BWGIC) registry. *EuroIntervention* 2014. [Epub ahead of print].

59. Ahmed B, Dauerman HL. Women, bleeding, and coronary intervention. *Circulation* 2013;**127**:641–649.

60. Park DW, Kim YH, Yun SC, Ahn JM, Lee JY, Kim WJ, Kang SJ, Lee SW, Lee CW, Park SW, Park SJ. Frequency, causes, predictors, and clinical significance of peri-procedural myocardial infarction following percutaneous coronary intervention. *Eur Heart J* 2013;**34**:1662–1669.

61. Mega JL, Hochman JS, Scirica BM, Murphy SA, Sloan S, McCabe CH, Merlini P, Morrow DA. Clinical features and outcomes of women with unstable ischemic heart disease: observations from metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndromes-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36). *Circulation* 2010;**121**:1809–1817.

62. Tamis-Holland JE, Lu J, Korytkowski M, Magee M, Rogers WJ, Lopes N, Mighton L, Jacobs AK, Bari D, Study Group. Sex differences in presentation and outcome among patients with type 2 diabetes and coronary artery disease treated with contemporary medical therapy with or without prompt revascularization: a report from the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation 2 Diabetes). *J Am Coll Cardiol* 2013;**61**:1767–1776.

63. Bertrand OF, Belisle P, Joyal D, Costerousse O, Rao SV, Jolly SS, Meerkin D, Joseph L. Comparison of transradial and femoral approaches for percutaneous coronary interventions: a systematic review and hierarchical Bayesian meta-analysis. *Am Heart J* 2012;**163**:632–648.

64. Shin JS, Tahk SJ, Yang HM, Yoon MH, Choi SY, Choi BJ, Lim HS, Lee YH, Seo KW, Park SJ, Choi YW, Yoon J, Youn YJ, Cho BR, Cha KS, Han KR, Hyon MS, Rha SW, Kim BO, Shin WY, Park KS, Cheong SS, Jeong MH. Impact of female gender on bleeding complications after transradial coronary intervention (from the Korean Transradial Coronary Intervention registry). *Am J Cardiol* 2014;**113**:2002–2006.

65. Abdelaal E, Brousseau-Provencher C, Montminy S, Plourde G, MacHaalany J, Bataille Y, Molin P, Dery JP, Barbeau G, Roy L, Larose E, De Larochelliere R, Nguyen CM, Proulx G, Costerousse O, Bertrand OF, Interventional Cardiologists at Quebec Heart-Lung Institute. Risk score, causes, and clinical impact of failure of transradial approach for percutaneous coronary interventions. *JACC Cardiovasc Interv* 2013;**6**:1129–1137.

66. Daugherty SL, Thompson LE, Kim S, Rao SV, Subherwal S, Tsai TT, Messenger JC, Masoudi FA. Patterns of use and comparative effectiveness of bleeding avoidance strategies in men and women following percutaneous coronary interventions: an observational study from the National Cardiovascular Data Registry. *J Am Coll Cardiol* 2013;**61**:2070–2078.

67. De Bruyne B, Fearon WF, Pijls NH, Barbato E, Tonino P, Piroth Z, Jagic N, Mobius-Winckler S, Rioufol G, Witt N, Kala P, MacCarthy P, Engstrom T, Oldroyd K, Mavromatis K, Manoharan G, Verlee P, Frobert O, Curzen N, Johnson JB, Limacher A, Nuesch E, Juni P, Fame Trial Investigators. Fractional flow reserve-guided PCI for stable coronary artery disease. *N Engl J Med* 2014;**371**:1208–1217.

68. Li J, Rihal CS, Matsuo Y, Elrashidi MY, Flammer AJ, Lee MS, Cassar A, Lennon RJ, Herrmann J, Bell MR, Holmes DR, Bresnahan JF, Hua Q, Lerman LO, Lerman A. Sex-related differences in fractional flow reserve-guided treatment. *Circ Cardiovasc Interv* 2013;**6**:662–670.

69. Kang SJ, Ahn JM, Han S, Lee JY, Kim WJ, Park DW, Lee SW, Kim YH, Lee CW, Park SW, Mintz GS, Park SJ. Sex differences in the visual-functional mismatch between coronary angiography or intravascular ultrasound versus fractional flow reserve. *JACC Cardiovasc Interv* 2013;**6**:562–568.

70. Regitz-Zagrosek V, Lehmkuhl E, Hocher B, Goesmann D, Lehmkuhl HB, Hausmann H, Hetzer R. Gender as a risk factor in young, not in old, women undergoing coronary artery bypass grafting. *J Am Coll Cardiol* 2004;**44**:2413–2414.

71. Lehmkuhl E, Kendel F, Gelbrich G, Dunkel A, Oertelt-Prigione S, Babitsch B, Knosalla C, Bairey-Merz N, Hetzer R, Regitz-Zagrosek V. Gender-specific predictors of early mortality after coronary artery bypass graft surgery. *Clin Res Cardiol* 2012;**101**:745–751.

72. Ferreira RG, Worthington A, Huang CC, Aranki SF, Muehlschlegel JD. Sex differences in the prevalence of diastolic dysfunction in cardiac surgical patients. *J Card Surg* 2015;**30**:238–245.

73. Kendel F, Dunkel A, Muller-Tasch T, Steinberg K, Lehmkuhl E, Hetzer R, Regitz-Zagrosek V. Gender differences in health-related quality of life after coronary bypass surgery: results from a 1-year follow-up in propensity-matched men and women. *Psychosom Med* 2011;**73**:280–285.

74. Kendel F, Gelbrich G, Wirtz M, Lehmkuhl E, Knoll N, Hetzer R, Regitz-Zagrosek V. Predictive relationship between depression and physical functioning after coronary surgery. *Arch Intern Med* 2010;**170**:1717–1721.

75. Kothawade K, Bairey Merz CN. Microvascular coronary dysfunction in women: pathophysiology, diagnosis, and management. *Curr Probl Cardiol* 2011;**36**:291–318.

76. Pepine CJ, Anderson RD, Sharaf BL, Reis SE, Smith KM, Handberg EM, Johnson BD, Sopko G, Bairey Merz CN. Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women's Ischemia Syndrome Evaluation) study. *J Am Coll Cardiol* 2010;**55**:2825–2832.

77. Murthy VL, Naya M, Taqueti VR, Foster CR, Gaber M, Hainer J, Dorbala S, Blankstein R, Rimoldi O, Camici PG, Di Carli MF. Effects of sex on coronary

microvascular dysfunction and cardiac outcomes. *Circulation* 2014;**129**: 2518–2527.

78. Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, Nodari S, Lam CS, Sato N, Shah AN, Gheorghiade M. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. *J Am Coll Cardiol* 2014;**63**:1123–1133.

79. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM, Vasan RS. Long-term trends in the incidence of and survival with heart failure. *N Engl J Med* 2002;**347**:1397–1402.

80. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *Eur Heart J* 2012;**33**:1787–1847.

81. Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, van Gilst WH, Widimsky J, Freemantle N, Eastaugh J, Mason J, Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. *Eur Heart J* 2003;**24**:442–463.

82. Regitz-Zagrosek V, Erdmann J, Wellnhofer E, Raible J, Fleck E. Novel mutation in the alpha-tropomyosin gene and transition from hypertrophic to hypocontractile dilated cardiomyopathy. *Circulation* 2000;**102**:E112–E116.

83. Codd MB, Sugrue DD, Gersh BJ, Melton LJ III. Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975–1984. *Circulation* 1989;**80**:564–572.

84. Coughlin SS, Comstock GW, Baughman KL. Descriptive epidemiology of idiopathic dilated cardiomyopathy in Washington County, Maryland, 1975–1991. *J Clin Epidemiol* 1993;**46**:1003–1008.

85. Regitz-Zagrosek V, Brokat S, Tschope C. Role of gender in heart failure with normal left ventricular ejection fraction. *Prog Cardiovasc Dis* 2007;**49**:241–251.

86. Lam CS, Carson PE, Anand IS, Rector TS, Kuskowski M, Komajda M, McKelvie RS, McMurray JJ, Zile MR, Massie BM, Kitzman DW. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. *Circ Heart Fail* 2012;**5**:571–578.

87. Kuch B, Muscholl M, Luchner A, Doring A, Riegger GA, Schunkert H, Hense HW. Gender specific differences in left ventricular adaptation to obesity and hypertension. *J Hum Hypertens* 1998;**12**:685–691.

88. Wheatley CM, Snyder EM, Johnson BD, Olson TP. Sex differences in cardiovascular function during submaximal exercise in humans. *SpringerPlus* 2014;**3**:445.

89. Hayward CS, Kalnins WV, Kelly RP. Gender-related differences in left ventricular chamber function. *Cardiovasc Res* 2001;**49**:340–350.

90. Gori M, Lam CS, Gupta DK, Santos AB, Cheng S, Shah AM, Claggett B, Zile MR, Kraigher-Krainer E, Pieske B, Voors AA, Packer M, Bransford T, Lefkowitz M, McMurray JJ, Solomon SD, Paramount Investigators. Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction. *Eur J Heart Fail* 2014;**16**:535–542.

91. Kararigas G, Dworatzek E, Petrov G, Summer H, Schulze TM, Baczko I, Knosalla C, Golz S, Hetzer R, Regitz-Zagrosek V. Sex-dependent regulation of fibrosis and inflammation in human left ventricular remodelling under pressure overload. *Eur J Heart Fail* 2014;**16**:1160–1167.

92. Riedinger MS, Dracup KA, Brecht ML, Padilla G, Sarna L, Ganz PA. Quality of life in patients with heart failure: do gender differences exist? *Heart Lung* 2001;**30**: 105–116.

93. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. *JAMA* 1994;**271**:840–844.

94. Agvall B, Dahlstrom U. Patients in primary health care diagnosed and treated as heart failure, with special reference to gender differences. *Scand J Prim Health Care* 2001;**19**:14–19.

95. Burstein JM, Yan R, Weller I, Abramson BL. Management of congestive heart failure: a gender gap may still exist. Observations from a contemporary cohort. *BMC Cardiovasc Disord* 2003;**3**:1.

96. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM, Comparison of Medical Therapy Pacing Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. *N Engl J Med* 2004;**350**:2140–2150.

97. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA III, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W, Madit-Crt Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events. *N Engl J Med* 2009;**361**:1329–1338.

98. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. *Circulation* 2013;**128**:1810–1852.

99. Arshad A, Moss AJ, Foster E, Padeletti L, Barsheshet A, Goldenberg I, Greenberg H, Hall WJ, McNitt S, Zareba W, Solomon S, Steinberg JS, Madit-Crt Executive Committee. Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial. *J Am Coll Cardiol* 2011; **57**:813–820.

100. Cheng YJ, Zhang J, Li WJ, Lin XX, Zeng WT, Tang K, Tang AL, He JG, Xu Q, Mei MY, Zheng DD, Dong YG, Ma H, Wu SH. More favorable response to cardiac resynchronization therapy in women than in men. *Circ Arrhythm Electrophysiol* 2014;**7**:807–815.

101. Zusterzeel R, Selzman KA, Sanders WE, Canos DA, O'Callaghan KM, Carpenter JL, Pina IL, Strauss DG. Cardiac resynchronization therapy in women: US Food and Drug Administration meta-analysis of patient-level data. *JAMA Intern Med* 2014;**174**:1340–1348.

102. Linde C, Stahlberg M, Benson L, Braunschweig F, Edner M, Dahlstrom U, Alehagen U, Lund LH. Gender, underutilization of cardiac resynchronization therapy, and prognostic impact of QRS prolongation and left bundle branch block in heart failure. *Europace* 2015;**17**:424–431.

103. Weymann A, Patil NP, Sabashnikov A, Mohite PN, Garcia Saez D, Amrani M, Bahrami T, De Robertis F, Wahlers T, Banner NR, Popov AF, Simon AR. Gender differences in continuous-flow left ventricular assist device therapy as a bridge to transplantation: a risk-adjusted comparison using a propensity score-matching analysis. *Artif Organs* 2015;**39**:212–219.

104. Regitz-Zagrosek V, Petrov G, Lehmkuhl E, Smits JM, Babitsch B, Brunhuber C, Jurmann B, Stein J, Schubert C, Merz NB, Lehmkuhl HB, Hetzer R. Heart transplantation in women with dilated cardiomyopathy. *Transplantation* 2010;**89**: 236–244.

105. Neuhauser H, Thamm M, Ellert U. [Blood pressure in Germany 2008–2011: results of the German Health Interview and Examination Survey for Adults (DEGS1)]. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* 2013; **56**:795–801.

106. Nwankwo T, Yoon SS, Burt V, Gu Q. Hypertension among adults in the United States: National Health and Nutrition Examination Survey, 2011–2012. *NCHS Data Brief* 2013;**133**:1–8.

107. Joham AE, Boyle JA, Zoungas S, Teede HJ. Hypertension in reproductive-aged women with polycystic ovary syndrome and association with obesity. *Am J Hypertens* 2015;**28**:847–851.

108. Barton M, Meyer MR. Postmenopausal hypertension: mechanisms and therapy. *Hypertension* 2009;**54**:11–18.

109. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Redon J, Dominiczak A, Narkiewicz K, Nilsson PM, Burnier M, Viigimaa M, Ambrosioni E, Caufield M, Coca A, Olsen MH, Schmieder RE, Tsioufis C, van de Borne P, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Clement DL, Coca A, Gillebert TC, Tendera M, Rosei EA, Ambrosioni E, Anker SD, Bauersachs J, Hitij JB, Caulfield M, De Buyzere M, De Geest S, Derumeaux GA, Erdine S, Farsang C, Funck-Brentano C, Gerc V, Germano G, Gielen S, Haller H, Hoes AW, Jordan J, Kahan T, Komajda M, Lovic D, Mahrholdt H, Olsen MH, Ostergren J, Parati G, Perk J, Polonia J, Popescu BA, Reiner Z, Ryden L, Sirenko Y, Stanton A, Struijker-Boudier H, Tsioufis C, van de Borne P, Vlachopoulos C, Volpe M, Wood DA. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur Heart J* 2013;**34**:2159–2219.

110. Gerdts E, Okin PM, de Simone G, Cramariuc D, Wachtell K, Boman K, Devereux RB. Gender differences in left ventricular structure and function during antihypertensive treatment: the Losartan Intervention for Endpoint Reduction in Hypertension Study. *Hypertension* 2008;**51**:1109–1114.

111. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. *JAMA* 1996;**275**:1557–1562.

112. Bushnell C, McCullough LD, Awad IA, Chireau MV, Fedder WN, Furie KL, Howard VJ, Lichtman JH, Lisabeth LD, Pina IL, Reeves MJ, Rexrode KM, Saposnik G, Singh V, Towfighi A, Vaccarino V, Walters MR, American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, Council for High Blood Pressure Research. Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2014;**45**:1545–1588.

113. Mancusi C, Gerdts E, De Simone G, Abdelhai YM, Lonnebakken MT, Boman K, Wachtell K, Dahlof B, Devereux RB. Impact of isolated systolic hypertension on normalization of left ventricular structure during antihypertensive treatment (the LIFE study). *Blood Press* 2014;**23**:206–212.

114. Regnault V, Thomas F, Safar ME, Osborne-Pellegrin M, Khalil RA, Pannier B, Lacolley P. Sex difference in cardiovascular risk: role of pulse pressure amplification. *J Am Coll Cardiol* 2012;**59**:1771–1777.

115. Siu SC, Silversides CK. Bicuspid aortic valve disease. *J Am Coll Cardiol* 2010;**55**:2789–2800.

116. Davies MJ, Treasure T, Parker DJ. Demographic characteristics of patients undergoing aortic valve replacement for stenosis: relation to valve morphology. *Heart* 1996;**75**:174–178.

117. Cramariuc D, Rogge BP, Lonnebakken MT, Boman K, Bahlmann E, Gohlke-Barwolf C, Chambers JB, Pedersen TR, Gerdts E. Sex differences in cardiovascular outcome during progression of aortic valve stenosis. *Heart* 2015;**101**:209–214.

118. Cramariuc D, Rieck AE, Staal EM, Wachtell K, Eriksen E, Rossebo AB, Gerdts E. Factors influencing left ventricular structure and stress-corrected systolic function in men and women with asymptomatic aortic valve stenosis (a SEAS Substudy). *Am J Cardiol* 2008;**101**:510–515.

119. Carroll JD, Carroll EP, Feldman T, Ward DM, Lang RM, McGaughey D, Karp RB. Sex-associated differences in left ventricular function in aortic stenosis of the elderly. *Circulation* 1992;**86**:1099–1107.

120. Villari B, Campbell SE, Schneider J, Vassalli G, Chiariello M, Hess OM. Sex-dependent differences in left ventricular function and structure in chronic pressure overload. *Eur Heart J* 1995;**16**:1410–1419.

121. Petrov G, Regitz-Zagrosek V, Lehmkuhl E, Krabatsch T, Dunkel A, Dandel M, Dworatzek E, Mahmoodzadeh S, Schubert C, Becher E, Hampl H, Hetzer R. Regression of myocardial hypertrophy after aortic valve replacement: faster in women? *Circulation* 2010;**122**(11 Suppl):S23–S28.

122. Petrov G, Dworatzek E, Schulze TM, Dandel M, Kararigas G, Mahmoodzadeh S, Knosalla C, Hetzer R, Regitz-Zagrosek V. Maladaptive remodeling is associated with impaired survival in women but not in men after aortic valve replacement. *JACC Cardiovasc Imaging* 2014;**7**:1073–1080.

123. Aggarwal SR, Clavel MA, Messika-Zeitoun D, Cueff C, Malouf J, Araoz PA, Mankad R, Michelena H, Vahanian A, Enriquez-Sarano M. Sex differences in aortic valve calcification measured by multidetector computed tomography in aortic stenosis. *Circ Cardiovasc Imaging* 2013;**6**:40–47.

124. Clavel MA, Pibarot P, Messika-Zeitoun D, Capoulade R, Malouf J, Aggarval S, Araoz PA, Michelena HI, Cueff C, Larose E, Miller JD, Vahanian A, Enriquez-Sarano M. Impact of aortic valve calcification, as measured by MDCT, on survival in patients with aortic stenosis: results of an international registry study. *J Am Coll Cardiol* 2014;**64**:1202–1213.

125. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H, Borger MA, Carrel TP, De Bonis M, Evangelista A, Falk V, Iung B, Lancellotti P, Pierard L, Price S, Schafers HJ, Schuler G, Stepinska J, Swedberg K, Takkenberg J, Von Oppell UO, Windecker S, Zamorano JL, Zembala M, Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology, European Association for Cardio-Thoracic Surgery. Guidelines on the management of valvular heart disease (version 2012). *Eur Heart J* 2012;**33**:2451–2496.

126. Bahlmann E, Cramariuc D, Gerdts E, Gohlke-Baerwolf C, Nienaber CA, Eriksen E, Wachtell K, Chambers J, Kuck KH, Ray S. Impact of pressure recovery on echocardiographic assessment of asymptomatic aortic stenosis: a SEAS substudy. *JACC Cardiovasc Imaging* 2010;**3**:555–562.

127. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard AD, Bavaria JE, Herrmann HC, Douglas PS, Petersen JL, Akin JJ, Anderson WN, Wang D, Pocock S, Partner Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. *N Engl J Med* 2010;**363**:1597–1607.

128. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Williams M, Dewey T, Kapadia S, Babaliaros V, Thourani VH, Corso P, Pichard AD, Bavaria JE, Herrmann HC, Akin JJ, Anderson WN, Wang D, Pocock SJ, Partner Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients. *N Engl J Med* 2011;**364**:2187–2198.

129. Williams M, Kodali SK, Hahn RT, Humphries KH, Nkomo VT, Cohen DJ, Douglas PS, Mack M, McAndrew TC, Svensson L, Thourani VH, Tuzcu EM, Weissman NJ, Kirtane AJ, Leon MB. Sex-related differences in outcomes after transcatheter or surgical aortic valve replacement in patients with severe aortic stenosis: Insights from the PARTNER Trial (Placement of Aortic Transcatheter Valve). *J Am Coll Cardiol* 2014;**63**:1522–1528.

130. Stangl V, Baldenhofer G, Knebel F, Zhang K, Sanad W, Spethmann S, Grubitzsch H, Sander M, Wernecke KD, Baumann G, Stangl K, Laule M. Impact of gender on three-month outcome and left ventricular remodeling after transfemoral transcatheter aortic valve implantation. *Am J Cardiol* 2012;**110**:884–890.

131. Zhao ZG, Liao YB, Peng Y, Chai H, Liu W, Li Q, Ren X, Wang XQ, Luo XL, Zhang C, Lu LH, Meng QT, Chen C, Chen M, Feng Y, Huang DJ. Sex-related differences in outcomes after transcatheter aortic valve implantation: a systematic review and meta-analysis. *Circ Cardiovasc Interv* 2013;**6**:543–551.

132. Stangl V, Baldenhofer G, Laule M, Baumann G, Stangl K. Influence of sex on outcome following transcatheter aortic valve implantation (TAVI): systematic review and meta-analysis. *J Interv Cardiol* 2014;**27**:531–539.

133. Lindman BR, Stewart WJ, Pibarot P, Hahn RT, Otto CM, Xu K, Devereux RB, Weissman NJ, Enriquez-Sarano M, Szeto WY, Makkar R, Miller DC, Lerakis S, Kapadia S, Bowers B, Greason KL, McAndrew TC, Lei Y, Leon MB, Douglas PS. Early regression of severe left ventricular hypertrophy after transcatheter aortic valve replacement is associated with decreased hospitalizations. *JACC Cardiovasc Interv* 2014;**7**:662–673.

134. Ribeiro HB, Webb JG, Makkar RR, Cohen MG, Kapadia SR, Kodali S, Tamburino C, Barbanti M, Chakravarty T, Jilaihawi H, Paradis JM, de Brito FS Jr, Canovas SJ, Cheema AN, de Jaegere PP, del Valle R, Chiam PT, Moreno R, Pradas G, Ruel M, Salgado-Fernandez J, Sarmento-Leite R, Toeg HD, Velianou JL, Zajarias A, Babaliaros V, Cura F, Dager AE, Manoharan G, Lerakis S, Pichard AD, Radhakrishnan S, Perin MA, Dumont E, Larose E, Pasian SG, Nombela-Franco L, Urena M, Tuzcu EM, Leon MB, Amat-Santos IJ, Leipsic J, Rodes-Cabau J. Predictive factors, management, and clinical outcomes of coronary obstruction following transcatheter aortic valve implantation: insights from a large multicenter registry. *J Am Coll Cardiol* 2013;**62**:1552–1562.

135. Ferrante G, Pagnotta P, Petronio AS, Bedogni F, Brambilla N, Fiorina C, Giannini C, Mennuni M, De Marco F, Klugmann S, Ettori F, Presbitero P. Sex differences in postprocedural aortic regurgitation and mid-term mortality after transcatheter aortic valve implantation. *Catheter Cardiovasc Interv* 2014;**84**:264–271.

136. Onorati F, D'Errigo P, Barbanti M, Rosato S, Covello RD, Maraschini A, Ranucci M, Santoro G, Tamburino C, Grossi C, Santini F, Menicanti L, Seccareccia F, Observant Research Group. Different impact of sex on baseline characteristics and major periprocedural outcomes of transcatheter and surgical aortic valve interventions: Results of the multicenter Italian OBSERVANT Registry. *J Thorac Cardiovasc Surg* 2014;**147**:1529–1539.

137. Avierinos JF, Inamo J, Grigioni F, Gersh B, Shub C, Enriquez-Sarano M. Sex differences in morphology and outcomes of mitral valve prolapse. *Ann Intern Med* 2008;**149**:787–795.

138. Levy D, Savage D. Prevalence and clinical features of mitral valve prolapse. *Am Heart J* 1987;**113**:1281–1290.

139. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP III, Guyton RA, O'Gara PT, Ruiz CE, Skubas NJ, Sorajja P, Sundt TM III, Thomas JD, American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2014;**63**:2438–2488.

140. Enriquez-Sarano M, Akins CW, Vahanian A. Mitral regurgitation. *Lancet* 2009;**373**:1382–1394.

141. Vassileva CM, McNeely C, Mishkel G, Boley T, Markwell S, Hazelrigg S. Gender differences in long-term survival of Medicare beneficiaries undergoing mitral valve operations. *Ann Thorac Surg* 2013;**96**:1367–1373.

142. Luzier AB, Killian A, Wilton JH, Wilson MF, Forrest A, Kazierad DJ. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. *Clin Pharmacol Ther* 1999;**66**:594–601.

143. Labbe L, Sirois C, Pilote S, Arseneault M, Robitaille NM, Turgeon J, Hamelin BA. Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. *Pharmacogenetics* 2000;**10**:425–438.

144. Thurmann PA. [Sex-specific differences in drug treatment]. *Ther Umsch* 2007;**64**:325–329.

145. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. *N Engl J Med* 2002;**347**:1403–1411.

146. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. *JAMA* 2003; **289**:871–878.

147. Verkerk AO, Wilders R, Veldkamp MW, de Geringel W, Kirkels JH, Tan HL. Gender disparities in cardiac cellular electrophysiology and arrhythmia susceptibility in human failing ventricular myocytes. *Int Heart J* 2005;**46**:1105–1118.

148. Kurokawa J, Tamagawa M, Harada N, Honda S, Bai CX, Nakaya H, Furukawa T. Acute effects of oestrogen on the guinea pig and human IKr channels and drug-induced prolongation of cardiac repolarization. *J Physiol* 2008;**586**(Pt 12): 2961–2973.

149. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. *N Engl J Med* 2005;**352**:1293–1304.

150. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. *BMJ* 2004;**329**:15–19.

151. Gurwitz JH. The age/gender interface in geriatric pharmacotherapy. *J Womens Health (Larchmt)* 2005;**14**:68–72.

152. Patel H, Bell D, Molokhia M, Srishanmuganathan J, Patel M, Car J, Majeed A. Trends in hospital admissions for adverse drug reactions in England: analysis of national hospital episode statistics 1998–2005. *BMC Clin Pharmacol* 2007;**7**:9.

153. Sikdar KC, Alaghehbandan R, MacDonald D, Barrett B, Collins KD, Donnan J, Gadag V. Adverse drug events in adult patients leading to emergency department visits. *Ann Pharmacother* 2010;**44**:641–649.

154. Franconi F, Campesi I. Sex and gender influences on pharmacological response: an overview. *Expert Rev Clin Pharmacol* 2014;**7**:469–485.

155. Franconi F, Campesi I. Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women. *Br J Pharmacol* 2014;**171**:580–594.

156. Catananti C, Liperoti R, Settanni S, Lattanzio F, Bernabei R, Fialova D, Landi F, Onder G. Heart failure and adverse drug reactions among hospitalized older adults. *Clin Pharmacol Ther* 2009;**86**:307–310.

157. United States General Accounting Office. *GAO-01-286R—Drug Safety: Most Drugs Withdrawn in Recent Years Had Greater Health Risks for Women*. U.S. Government Printing Office; Washington, 2001.

158. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL. How to improve R&D productivity: the pharmaceutical industry's grand challenge. *Nat Rev Drug Discov* 2010;**9**:203–214.

159. Regitz-Zagrosek V, Seeland U. Sex and gender differences in clinical medicine. In: Regitz-Zagrosek V (ed.), *Handbook of Experimental Pharmacology*. Berlin,Heidelberg: Springer; 2012. p3–22.

160. Bailey KR. Reporting of sex-specific results: a statistician's perspective. *Mayo Clin Proc* 2007;**82**:158.

161. Hankivsky O. Women's health, men's health, and gender and health: implications of intersectionality. *Soc Sci Med* 2012;**74**:1712–1720.

162. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L, Cardiac Resynchronization-Heart Failure Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. *N Engl J Med* 2005;**352**:1539–1549.

163. St John Sutton M, Ghio S, Plappert T, Tavazzi L, Scelsi L, Daubert C, Abraham WT, Gold MR, Hassager C, Herre JM, Linde C, REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) Study Group. Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association class I/II heart failure. *Circulation* 2009;**120**:1858–1865.

164. Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, Hohnloser SH, Nichol G, Birnie DH, Sapp JL, Yee R, Healey JS, Rouleau JL, Resynchronization-Defibrillation for Ambulatory Heart Failure Trial Investigators. Cardiac-resynchronization therapy for mild-to-moderate heart failure. *N Engl J Med* 2010;**363**:2385–2395.

165. Yukawa E, Honda T, Ohdo S, Higuchi S, Aoyama T. Population-based investigation of relative clearance of digoxin in Japanese patients by multiple trough screen analysis: an update. *J Clin Pharmacol* 1997;**37**:92–100.

166. Drici MD, Knollmann BC, Wang WX, Woosley RL. Cardiac actions of erythromycin: influence of female sex. *JAMA* 1998;**280**:1774–1776.

167. Ebert SN, Liu XK, Woosley RL. Female gender as a risk factor for drug-induced cardiac arrhythmias: evaluation of clinical and experimental evidence. *J Womens Health* 1998;**7**:547–557.

168. Lehmann MH, Hardy S, Archibald D, quart B, MacNeil DJ. Sex difference in risk of torsade de pointes with d,l-sotalol. *Circulation* 1996;**94**:2535–2541.

169. Liu XK, Katchman A, Drici MD, Ebert SN, Ducic I, Morad M, Woosley RL. Gender difference in the cycle length-dependent QT and potassium currents in rabbits. *J Pharmacol Exp Ther* 1998;**285**:672–679.

170. Locati EH, Zareba W, Moss AJ, Schwartz PJ, Vincent GM, Lehmann MH, Towbin JA, Priori SG, Napolitano C, Robinson JL, Andrews M, Timothy K, Hall WJ. Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry. *Circulation* 1998;**97**:2237–2244.

171. Rodenburg EM, Stricker BH, Visser LE. Sex-related differences in hospital admissions attributed to adverse drug reactions in the Netherlands. *Br J Clin Pharmacol* 2011;**71**:95–104.

172. Toss H, Wallentin L, Siegbahn A. Influences of sex and smoking habits on anticoagulant activity in low-molecular-weight heparin treatment of unstable coronary artery disease. *Am Heart J* 1999;**137**:72–78.

173. Fang MC, Singer DE, Chang Y, Hylek EM, Henault LE, Jensvold NG, Go AS. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. *Circulation* 2005;**112**:1687–1691.

174. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA, Oasis-Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. *JAMA* 2006;**295**:1519–1530.

175. Chacko M, Lincoff AM, Wolski KE, Cohen DJ, Bittl JA, Lansky AJ, Tsuchiya Y, Betriu A, Yen MH, Chew DP, Cho L, Topol EJ. Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial. *Am Heart J* 2006;**151**:1032.e1–e7.

176. Shaw LJ1, Merz CN, Pepine CJ, Reis SE, Bittner V, Kip KE, Kelsey SF, Olson M, Johnson BD, Mankad S, Sharaf BL, Rogers WJ, Pohost GM, Sopko G. Women's Ischemia Syndrome Evaluation (WISE) Investigators. The economic burden of angina in women with suspected ischemic heart disease: results from the National Institutes of Health–National Heart, Lung, and Blood Institute–sponsored Women's Ischemia Syndrome Evaluation. *Circulation* 2006;**114**:894–904.